{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:44:08Z","timestamp":1789602248659,"version":"build-2803163510"},"reference-count":27,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.18553\/jmcp.2024.24049","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:17:24Z","timestamp":1721841444000},"page":"1106-1116","source":"Crossref","is-referenced-by-count":4,"title":["Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton\u2019s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting"],"prefix":"10.18553","volume":"30","author":[{"given":"Scott F.","family":"Huntington","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenish S.","family":"Manzoor","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dureshahwar","family":"Jawaid","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Puckett","sequence":"additional","affiliation":[{"name":"COVIA Health Solutions, Ambler, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnadozie","family":"Emechebe","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arliene","family":"Ravelo","sequence":"additional","affiliation":[{"name":"Genentech Inc., South San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kamal-Bahl","sequence":"additional","affiliation":[{"name":"COVIA Health Solutions, Ambler, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalpa A.","family":"Doshi","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw547"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.368"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096107"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0715-5"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00637-1"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"R10","unstructured":"Swaminathan M. Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia? Targeted Oncology. Published September 7, 2023. Accessed November 17, 2023. https:\/\/www.targetedonc.com\/view\/is-fixed-duration-therapy-the-new-standard-of-care-in-frontline-chronic-lymphocytic-leukemia-"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000233"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2943"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00375-x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010108"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199685028.001.0001"},{"key":"R20","author":"Li Z","year":"2010","journal-title":"SAS Global Forum"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238735"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000120"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1929894"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015461"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19510"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967492.06443.0a"},{"key":"R27","unstructured":"Raymakers AJN, Kesselheim AS, Rome BN. Medicare price negotiation: The example of ibrutinib. Accessed May 10, 2024. https:\/\/www.healthaffairs.org\/content\/forefront\/medicare-price-negotiation-under-inflation-reduction-act-example-ibrutinib"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168152"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.010"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:22:56Z","timestamp":1727292176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2024.24049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.18553\/jmcp.2024.24049"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2024.24049","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}